B-cell populations and sub-populations in Sjögren's syndrome

Presse Medicale

Volumn 41, Issue 9 PART2, 2012, Pages

  Hamza, Nishath ^a   Bos, Nicolaas A ^a   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR ANTIBOBY; BELIMUMAB; CD27 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; LA ANTIBODY; MONOCLONAL ANTIBODY; RITUXIMAB; RO ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; B LYMPHOCYTE; BAFF GENE; BLOOD; GENE; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; PRIMARY SJOEGREN SYNDROME; PROTEIN TARGETING; SALIVARY GLAND; SHORT SURVEY; SJOEGREN SYNDROME;

EID: 84865960201     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.05.021     Document Type: Short Survey

References (74)

1. Fox R.I. Sjogren's syndrome. Lancet 2005, 366:321-331.
2. Gaubitz M. Epidemiology of connective tissue disorders. Rheumatology (Oxford) 2006, 45:3-4.
3. Pender M.P., Tabi Z., Nguyen K.B., McCombe P.A. The proximal peripheral nervous system is a major site of demyelination in experimental autoimmune encephalomyelitis induced in the Lewis rat by a myelin basic protein-specific T cell clone. Acta Neuropathol 1995, 89:527-531.
4. Radbruch A., Thiel A. Cell therapy for autoimmune diseases: does it have a future. Ann Rheum Dis 2004, 63:96-101.
5. Theander E., Vasaitis L., Baecklund E., Nordmark G., Warfvinge G., Liedholm R., et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 2011, 70:1363-1368.
6. Salomonsson S., Jonsson M.V., Skarstein K., Brokstad K.A., Hjelmstrom P., Wahren-Herlenius M., et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum 2003, 48:3187-3201.
7. Kallenberg C.G., Vissink A., Kroese F.G., Abdulahad W.H., Bootsma H. What have we learned from clinical trials in primary Sjogren's syndrome about pathogenesis?. Arthritis Res Ther 2011, 13:205.
8. Abdulahad W.H., Meijer J.M., Kroese F.G., Meiners P.M., Vissink A., Spijkervet F.K., et al. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjogren's syndrome: a double-blind, placebo-controlled study. Arthritis Rheum 2011, 63:1116-1123.
9. Hansen A., Odendahl M., Reiter K., Jacobi A.M., Feist E., Scholze J., et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002, 46:2160-2171.
10. Bohnhorst J.O., Bjorgan M.B., Thoen J.E., Jonsson R., Natvig J.B., Thompson K.M. Abnormal B cell differentiation in primary Sjogren's syndrome results in a depressed percentage of circulating memory B cells and elevated levels of soluble CD27 that correlate with Serum IgG concentration. Clin Immunol 2002, 103:79-88.
11. Bohnhorst J.O., Bjorgan M.B., Thoen J.E., Natvig J.B., Thompson K.M. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol 2001, 167:3610-3618.
12. Binard A., Le Pottier L., Devauchelle-Pensec V., Saraux A., Youinou P., Pers J.O. Is the blood B-cell subset profile diagnostic for Sjogren syndrome. Ann Rheum Dis 2009, 68:1447-1452.
13. Hansen A., Reiter K., Ziprian T., Jacobi A., Hoffmann A., Gosemann M., et al. Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjogren's syndrome. Arthritis Rheum 2005, 52:2109-2119.
14. Fecteau J.F., Cote G., Neron S. A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation. J Immunol 2006, 177:3728-3736.
15. Wei C., Anolik J., Cappione A., Zheng B., Pugh-Bernard A., Brooks J., et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007, 178:6624-6633.
16. Abdulahad W.H., Kroese F.G., Vissink A., Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. J Autoimmun 2012, http://dx.doi.org/10.1016/j.jaut.2012.01.009.
17. Duty J.A., Szodoray P., Zheng N.Y., Koelsch K.A., Zhang Q., Swiatkowski M., et al. Functional energy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med 2009, 206:139-151.
18. Szyszko E.A., Brun J.G., Skarstein K., Peck A.B., Jonsson R., Brokstad K.A. Phenotypic diversity of peripheral blood plasma cells in primary Sjogren's syndrome. Scand J Immunol 2011, 73:18-28.
19. Zhan F., Hardin J., Kordsmeier B., Bumm K., Zheng M., Tian E., et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002, 99:1745-1757.
20. Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.L., Moreau P., et al. The phenotype of normal, reactive and malignant plasma cells. Identification of many and multiple myelomas and of new targets for myeloma therapy. Haematologica 2006, 91:1234-1240.
21. Medina F., Segundo C., Campos-Caro A., Gonzalez-Garcia I., Brieva J.A. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 2002, 99:2154-2161.
22. Youinou P., vauchelle-Pensec V., Pers J.O. Significance of B cells and B cell clonality in Sjogren's syndrome. Arthritis Rheum 2010, 62:2605-2610.
23. Chung J.B., Silverman M., Monroe J.G. Transitional B cells: step-by-step towards immune competence. Trends Immunol 2003, 24:343-349.
24. Youinou P., Pers J.O. The late news on baff in autoimmune diseases. Autoimmun Rev 2010, 9:804-806.
25. Larsson A., Bredberg A., Henriksson G., Manthorpe R., Sallmyr A. Immunohistochemistry of the B-cell component in lower lip salivary glands of Sjogren's syndrome and healthy subjects. Scand J Immunol 2005, 61:98-107.
26. Szyszko E.A., Brokstad K.A., Oijordsbakken G., Jonsson M.V., Jonsson R., Skarstein K. Salivary glands of primary Sjogren's syndrome patients express factors vital for plasma cell survival. Arthritis Res Ther 2011, 13:R2.
27. Stott D.I., Hiepe F., Hummel M., Steinhauser G., Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J Clin Invest 1998, 102:938-946.
28. Bahler D.W., Swerdlow S.H. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjogren's syndrome) begin as nonmalignant antigen-selected expansions. Blood 1998, 91:1864-1872.
29. Gellrich S., Rutz S., Borkowski A., Golembowski S., Gromnica-Ihle E., Sterry W., et al. Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjogren's syndrome. Arthritis Rheum 1999, 42:240-247.
30. Hamza N., Bootsma H., Yuvaraj S., Spijkervet F.K.L., Haacke E.A., Pollard R.P.E., et al. Persistence of immunoglobulin-producing cells in parotid salivary glands of primary Sjögren's syndrome patients after B-cell depletion therapy. Ann Rheum Dis 2012, 10.1136/annrheumdis-2011-201189.
31. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
32. Tengner P., Halse A.K., Haga H.J., Jonsson R., Wahren-Herlenius M. Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjogren's syndrome. Arthritis Rheum 1998, 41:2238-2248.
33. Aqrawi L.A., Skarstein K., Bredholt G., Brun J.G., Brokstad K.A. Autoantigen-specific memory B cells in primary Sjogren's syndrome. Scand J Immunol 2012, 75:61-68.
34. Amft N., Curnow S.J., Scheel-Toellner D., Devadas A., Oates J., Crocker J., et al. Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren's syndrome. Arthritis Rheum 2001, 44:2633-2641.
35. Shi G.X., Harrison K., Wilson G.L., Moratz C., Kehrl J.H. RGS13 regulates germinal center B lymphocytes responsiveness to CXC chemokine ligand (CXCL)12 and CXCL13. J Immunol 2002, 169:2507-2515.
36. Legler D.F., Loetscher M., Roos R.S., Clark-Lewis I., Baggiolini M., Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998, 187:655-660.
37. Ansel K.M., Ngo V.N., Hyman P.L., Luther S.A., Forster R., Sedgwick J.D., et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000, 406:309-314.
38. Mackay F., Schneider P., Rennert P., Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003, 21:231-264.
39. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002, 109:59-68.
40. Jonsson M.V., Szodoray P., Jellestad S., Jonsson R., Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 2005, 25:189-201.
41. Daridon C., Devauchelle V., Hutin P., Le Berre R., Martins-Carvalho C., Bendaoud B., et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 2007, 56:1134-1144.
42. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
43. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003, 62:168-171.
44. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005, 1050:34-39.
45. Szodoray P., Alex P., Jonsson M.V., Knowlton N., Dozmorov I., Nakken B., et al. Distinct profiles of Sjogren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 2005, 117:168-176.
46. d'Arbonneau F., Pers J.O., Devauchelle V., Pennec Y., Saraux A., Youinou P. BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjogren's syndrome. Arthritis Rheum 2006, 54:115-126.
47. Wiglesworth A.K., Ennis K.M., Kockler D.R. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus. Ann Pharmacother 2010, 44:1955-1961.
48. Varin M.M., Le Pottier L., Youinou P., Saulep D., Mackay F., Pers J.O. B-cell tolerance breakdown in Sjogren's syndrome: focus on BAFF. Autoimmun Rev 2010, 9:604-608.
49. Varin M.M., Guerrier T., Devauchelle-Pensec V., Jamin C., Youinou P., Pers J.O. Sjogren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmun Rev 2012, 11:252-258.
50. Mecklenbrauker I., Kalled S.L., Leitges M., Mackay F., Tarakhovsky A. Regulation of B-cell survival by BAFF-dependent PKCdelta-mediated nuclear signalling. Nature 2004, 431:456-461.
51. Kaschner S., Hansen A., Jacobi A., Reiter K., Monson N.L., Odendahl M., et al. Immunoglobulin Vlambda light chain gene usage in patients with Sjogren's syndrome. Arthritis Rheum 2001, 44:2620-2632.
52. Heimbacher C., Hansen A., Pruss A., Jacobi A., Reiter K., Lipsky P.E., et al. Immunoglobulin Vkappa light chain gene analysis in patients with Sjogren's syndrome. Arthritis Rheum 2001, 44:626-637.
53. Hansen A., Jacobi A., Pruss A., Kaufmann O., Scholze J., Lipsky P.E., et al. Comparison of immunoglobulin heavy chain rearrangements between peripheral and glandular B cells in a patient with primary Sjogren's syndrome. Scand J Immunol 2003, 57:470-479.
54. Redpath S., Michaelsen T.E., Sandlie I., Clark M.R. The influence of the hinge region length in binding of human IgG to human Fcgamma receptors. Hum Immunol 1998, 59:720-727.
55. Meijer J.M., Meiners P.M., Vissink A., Spijkervet F.K., Abdulahad W., Kamminga N., et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:960-968.
56. Dass S., Bowman S.J., Vital E.M., Ikeda K., Pease C.T., Hamburger J., et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008, 67:1541-1544.
57. Meijer J.M., Pijpe J., Vissink A., Kallenberg C.G., Bootsma H. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009, 68:284-285.
58. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005, 52:2740-2750.
59. Pijpe J., Meijer J.M., Bootsma H., van der Waal J.E., Spijkervet F.K., Kallenberg C.G., et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren's syndrome. Arthritis Rheum 2009, 60:3251-3256.
60. Devauchelle-Pensec V., Pennec Y., Morvan J., Pers J.O., Daridon C., Jousse-Joulin S., et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007, 57:310-317.
61. Pers J.O., Devauchelle V., Daridon C., Bendaoud B., Le B.R., Bordron A., et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 2007, 56:1464-1477.
62. Withers D.R., Fiorini C., Fischer R.T., Ettinger R., Lipsky P.E., Grammer A.C. T cell-dependent survival of CD20+ and. Blood 2007, 109:4856-4864.
63. Hamaguchi Y., Uchida J., Cain D.W., Venturi G.M., Poe J.C., Haas K.M., et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 2005, 174:4389-4399.
64. Gong Q., Ou Q., Ye S., Lee W.P., Cornelius J., Diehl L., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005, 174:817-826.
65. Vugmeyster Y., Howell K., McKeever K., Combs D., Canova-Davis E. Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. Int Immunopharmacol 2003, 3:1477-1481.
66. Anolik J.H., Barnard J., Owen T., Zheng B., Kemshetti S., Looney R.J., et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007, 56:3044-3056.
67. Mraz M., Zent C.S., Church A.K., Jelinek D.F., Wu X., Pospisilova S., et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol 2011, 155(1):53-64.
68. Hiepe F., Dorner T., Hauser A.E., Hoyer B.F., Mei H., Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011, 7:170-178.
69. Cambridge G., Isenberg D.A., Edwards J.C., Leandro M.J., Migone T.S., Teodorescu M., et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008, 67:1011-1016.
70. Lu T.Y., Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009, 61:482-487.
71. Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., Isenberg D.A. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007, 66:1259-1262.
72. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007, 66:351-357.
73. Liu Z., Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol 2011, 32:388-394.
74. Meiners P.M., Vissink A., Kallenberg C.G., Kroese F.G., Bootsma H. Treatment of primary Sjogren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?. Expert Opin Biol Ther 2011, 11:1381-1394.